Trial Profile
A Phase I Study to Evaluate the Safety, Tolerability, and Effect of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), on Markers of HIV Persistence in ART-treated, HIV-infected Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs VRC 01 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 28 Mar 2017 New trial record
- 16 Feb 2017 Primary endpoint of cell-associated HIV-1 RNA/DNA ratio in total CD4+ cells has not been met, according to results presented at the 24th Conference on Retroviruses and Opportunistic Infections.
- 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections